HomeCompareAGTC vs QYLD

AGTC vs QYLD: Dividend Comparison 2026

AGTC yields 508.13% · QYLD yields 11.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 AGTC wins by $69571.54M in total portfolio value
10 years
AGTC
AGTC
● Live price
508.13%
Share price
$0.39
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$69571.56M
Annual income
$50,154,845,926.92
Full AGTC calculator →
QYLD
Global X Nasdaq 100 Covered Call ETF
● Live price
11.92%
Share price
$17.15
Annual div
$2.04
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.4K
Annual income
$5,659.31
Full QYLD calculator →

Portfolio growth — AGTC vs QYLD

📍 AGTC pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAGTCQYLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AGTC + QYLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
AGTC pays
QYLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AGTC
Annual income on $10K today (after 15% tax)
$43,191.06/yr
After 10yr DRIP, annual income (after tax)
$42,631,619,037.88/yr
QYLD
Annual income on $10K today (after 15% tax)
$1,013.51/yr
After 10yr DRIP, annual income (after tax)
$4,810.41/yr
At 15% tax rate, AGTC beats the other by $42,631,614,227.47/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AGTC + QYLD for your $10,000?

AGTC: 50%QYLD: 50%
100% QYLD50/50100% AGTC
Portfolio after 10yr
$34785.79M
Annual income
$25,077,425,793.12/yr
Blended yield
72.09%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on AGTC right now

AGTC
Analyst Ratings
9
Buy
5
Hold
Consensus: Buy
QYLD
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AGTC buys
0
QYLD buys
0
No recent congressional trades found for AGTC or QYLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAGTCQYLD
Forward yield508.13%11.92%
Annual dividend / share$2.00$2.04
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$69571.56M$25.4K
Annual income after 10y$50,154,845,926.92$5,659.31
Total dividends collected$67890.24M$27.1K
Payment frequencyquarterlymonthly
SectorStockETF

Year-by-year: AGTC vs QYLD ($10,000, DRIP)

YearAGTC PortfolioAGTC Income/yrQYLD PortfolioQYLD Income/yrGap
1← crossover$61,513$50,813.01$10,352$1,192.36+$51.2KAGTC
2$357,937$292,117.85$10,830$1,347.57+$347.1KAGTC
3$1,971,589$1,588,596.72$11,460$1,539.07+$1.96MAGTC
4$10,287,466$8,177,865.69$12,275$1,777.84+$10.28MAGTC
5$50,886,951$39,879,362.52$13,323$2,078.95+$50.87MAGTC
6$238,807,233$184,358,195.45$14,667$2,463.34+$238.79MAGTC
7$1,064,097,636$808,573,896.33$16,396$2,960.57+$1064.08MAGTC
8$4,505,792,438$3,367,207,967.63$18,631$3,612.97+$4505.77MAGTC
9$18,146,463,265$13,325,265,356.46$21,548$4,482.15+$18146.44MAGTC
10$69,571,561,621$50,154,845,926.92$25,398$5,659.31+$69571.54MAGTC

AGTC vs QYLD: Complete Analysis 2026

AGTCStock

Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. Its advanced product candidates include three ophthalmology development programs across two targets, including X-linked retinitis pigmentosa, which is in the Phase 1/2 clinical trials; and achromatopsia that is in Phase 1/2 clinical trials. It is also developing an optogenetic product candidate to treat advanced retinal disease. In addition, the company has initiated one preclinical program in otology; preclinical program in dry age-related macular degeneration; and two preclinical programs in targeting central nervous system disorders, including frontotemporal dementia and amyotrophic lateral sclerosis. It has collaboration agreements with University of Florida; Bionic Sight, Inc.; and Otonomy, Inc. The company was incorporated in 1999 and is headquartered in Alachua, Florida.

Full AGTC Calculator →

QYLDETF

The Global X Nasdaq 100 Covered Call ETF (QYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe Nasdaq-100 BuyWrite V2 Index.

Full QYLD Calculator →
📬

Get this AGTC vs QYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AGTC vs SCHDAGTC vs JEPIAGTC vs OAGTC vs KOAGTC vs MAINAGTC vs XYLDAGTC vs JEPQAGTC vs RYLD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.